While its biggest immunology drug Remicade showed moderate growth of 5.2%, the sales for Simponi and Stelara grew substantially.

FORBES: Johnson & Johnson's Earnings Buoyed By Pharma Strength

Simponi and Stelara did well internationally, especially in Japan.

FORBES: Johnson & Johnson's Earnings Buoyed By Pharma Strength

Approvals for new drugs such as Stelara, which treats psoriasis, the prostate cancer drug Zytiga and the adult schizophrenia drug Invega Sustenna, showed strong sales results during the quarter, the company said.

FORBES: Johnson & Johnson Beats Estimates, Profit Falls On Domestic Recalls